Cargando…

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

PURPOSE: Combination therapy with insulin-independent sodium-glucose cotransporter 2 inhibitors and thiazolidinedione drugs, such as lobeglitazone, has been reported to elicit potential additive efficacy in glycemic control in type 2 diabetes mellitus. This study was conducted to evaluate the pharma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yu Kyong, Hwang, Jun Gi, Park, Min Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089085/ https://www.ncbi.nlm.nih.gov/pubmed/33953542 http://dx.doi.org/10.2147/DDDT.S302215

Ejemplares similares

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
por: Lee, Min A, et al.
Publicado: (2017)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway
por: Jin, Jun-Qing, et al.
Publicado: (2021)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
por: Kim, Dasohm, et al.
Publicado: (2023)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
por: Lee, Yu Seol, et al.
Publicado: (2018)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

Drug–drug interaction study of ciprofol and sodium divalproex: Pharmacokinetics, pharmacodynamics, and safety in healthy Chinese subjects
por: Yang, Dandan, et al.
Publicado: (2023)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism
por: Kim, Seok-Ho, et al.
Publicado: (2019)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

Empagliflozin: a potential anticancer drug
por: Wu, Wenwen, et al.
Publicado: (2023)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Empagliflozin: Novel antidiabetes and pro-cardiac drug
por: Raut, Monish S, et al.
Publicado: (2017)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Pharmacokinetic relevance of glomerular hyperfiltration for drug dosing
por: Zoccali, Carmine, et al.
Publicado: (2023)

Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions
por: Hailat, Mohammad, et al.
Publicado: (2022)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis
por: Suzuki, Shugo, et al.
Publicado: (2016)

Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis
por: Zhang, Yu, et al.
Publicado: (2017)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs
por: Puhl, Ana C., et al.
Publicado: (2015)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
por: Son, Yu-Jeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kkkd6uj93mc09ct7vggilhl64n